Login
$OGN
$13.90 +$0.00 (0.0%) After hours

$OGN SEC Filings

Filed On Filing
10 Nov 2026 Form 4: Drinane Juliana Papa, Head of Mfg & Supply

Received 3,626 shares by exercise or conversion · Gave up 1,242 shares to cover exercise price or tax ($17.2K)

10 Nov 2026 Form 4: Arjona Ferreira Juan Camilo, Head of R&D & CMO

Received 6,447 shares by exercise or conversion · Gave up 2,314 shares to cover exercise price or tax ($32.1K)

10 Nov 2026 Form 4: Holzbaur Lynette, SVP and Corporate Controller

Received 3,038 shares by exercise or conversion · Gave up 866 shares to cover exercise price or tax ($12K) · Received 2,418 shares by exercise or conversion · 1 more

30 Oct 2026 8-K: Regulation FD Disclosure

This exhibit provides certain supplemental non-GAAP financial measures for the quarter ended September 30, 2026. As disclosed in the accompanying Current Report on Form 8-K, Organon & Co. (the “Company”) is furnishing this information in...

30 Oct 2026 10-Q
14 Aug 2026 SCHEDULE 13G
12 Aug 2026 Form 4: Arjona Ferreira Juan Camilo, Head of R&D & CMO

Received 11,519 shares by exercise or conversion · Gave up 4,134 shares to cover exercise price or tax ($56.3K) · Acquired 11,519 Restricted Stock Units (Option Exercise/Conversion)

05 Aug 2026 144
05 Aug 2026 Form 4: Drinane Juliana Papa, Head of Mfg & Supply

Sold 14,761 shares ($200K)

31 Jul 2026 SCHEDULE 13G/A
31 Jul 2026 8-K: Regulation FD Disclosure

This exhibit provides certain supplemental non-GAAP financial measures for the quarter ended June 30, 2026. As disclosed in the accompanying Current Report on Form 8-K, Organon & Co. (the “Company”) is furnishing this information in lieu...

31 Jul 2026 10-Q
23 Jul 2026 8-K: Submission of Matters to a Vote of Security Holders

A special meeting of stockholders (the “Special Meeting”) of Organon & Co., a Delaware corporation (the “Company”), was held on July 23, 2026 at 10:00 a.m., Eastern Time, via a virtual meeting website. The Special Meeting was held in ord...

17 Jul 2026 DEFA14A
17 Jul 2026 8-K: Other Events

As previously disclosed, on April 26, 2026, Organon & Co., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Sun Pharmaceutical Holdings USA, Inc. (“Su...

17 Jun 2026 DEFM14A
15 Jun 2026 Form 4: Sharp Shalini, Director

Granted 17,857.143 Phantom Stock ($240K)

15 Jun 2026 Form 4: Sequeira Ramona, Director

Granted 17,857.143 Phantom Stock ($240K)

15 Jun 2026 Form 4: Patton Cynthia M, Director

Granted 17,857.143 Phantom Stock ($240K)

15 Jun 2026 Form 4: Ozuah Philip, Director

Granted 17,857.143 Phantom Stock ($240K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support